Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Is Bluebird Bio Stock a Buy?

TheMotleyFool

0 0

Is Bluebird Bio Stock a Buy?Photo, wide shot, wide-angle lens, Medical device manufacturer, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Michael Light: https://img.theapi.app/temp/3a7f6312-1eee-4702-9005-93cc1e62f970.png

Once a rising star in the biotech industry, Bluebird Bio (NASDAQ: BLUE) has had a difficult past few years. The company's shares are down by 94% since late 2018, a horrible performance by any metric. However, this biotech specialist has some redeeming qualities. Unlike most of its peers in the gene-editing niche, Bluebird has earned approval for several of its products, a testament to the company's innovative abilities.

Furthermore, Bluebird's market capitalization is just $314 million as of this writing, lower than many of its clinical-stage competitors. Is Bluebird Bio stock a buy at current levels?